Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue					2M -
gross profit					-2M -
selling and marketing expenses					-300K -
general and administrative expenses	1.66M -	3.85M 132.39%	18.66M 385.26%	37.35M 100.14%	32.61M 12.70%
selling general and administrative expenses	1.66M -	3.85M 132.39%	18.66M 385.26%	37.35M 100.14%	32.31M 13.50%
research and development expenses	1.22M -	9.05M 639.22%	51.05M 464.26%	86.13M 68.70%	47.89M 44.40%
other expenses			181K -
cost and expenses	2.88M -	12.89M 347.86%	69.72M 440.69%	123.48M 77.12%	82.20M 33.43%
operating expenses	2.88M -	12.89M 347.86%	69.72M 440.69%	123.48M 77.12%	80.20M 35.05%
interest expense				-2.76M -
ebitda	-2.88M -	-12.43M 331.57%	-63.49M 410.95%	-123.48M 94.50%	-80.20M 35.05%
operating income	-2.88M -	-12.89M 347.86%	-69.72M 440.69%	-123.48M 77.12%	-82.20M 33.43%
depreciation and amortization		469K -	6.23M 1,228.57%	709K 88.62%	2M 182.09%
total other income expenses net	107K -	66K 38.32%	-6.26M 9,581.82%	2.76M 144.17%	8.41M 204.12%
income before tax	-2.77M -	-12.83M 362.77%	-75.97M 492.26%	-120.72M 58.89%	-73.79M 38.87%
income tax expense	-107K -	-66K 38.32%	5.56M 8,525.76%	-2.76M 149.70%
net income	-2.67M -	-12.76M 378.87%	-81.54M 538.90%	-117.95M 44.66%	-73.79M 37.44%
weighted average shs out	21.98M -	22.13M 0.69%	8.49M 61.61%	33.03M 288.93%	39.90M 20.80%
weighted average shs out dil	21.98M -	22.13M 0.69%	8.49M 61.61%	33.03M 288.93%	39.90M 20.80%
eps	-0.12 -	-0.58 383.33%	-9.60 1,555.17%	-3.57 62.81%	-1.85 48.18%
epsdiluted	-0.12 -	-0.58 383.33%	-9.60 1,555.17%	-3.57 62.81%	-1.85 48.18%

COM:PYXISONCOLOGY

Pyxis Oncology, Inc.

Last Close

3.82

21/11 21:00

Market Cap

174.31M

Beta: -

Volume Today

15.04M

Avg: -

Preview